Dutch company of Alnylam Pharmaceuticals, the US RNA interference biotechnology company, which holds European marketing authorisations and supplies its RNAi therapeutics for rare diseases such as amyloidosis and acute hepatic porphyria.
No comments available.
Leave your rating & comment